--- title: "Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month High - Should You Buy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/278440434.md" description: "Relmada Therapeutics (NASDAQ:RLMD) reached a new 52-week high of $7.05, closing at $6.9830 with significant trading volume. Analysts have mixed ratings: Weiss Ratings maintains a 'sell' rating, while Jefferies and Lucid Cap Mkts have issued 'buy' ratings with price targets of $9.00 and higher. The stock has a market cap of $534.38 million and a price-to-earnings ratio of -4.07. Insider trading shows CFO Maged Shenouda increased his stake, and institutional investors hold 45.24% of shares. Relmada focuses on developing therapies for CNS disorders, particularly for depression and pain." datetime: "2026-03-09T20:01:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278440434.md) - [en](https://longbridge.com/en/news/278440434.md) - [zh-HK](https://longbridge.com/zh-HK/news/278440434.md) --- # Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month High - Should You Buy? Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The company traded as high as $7.05 and last traded at $6.9830, with a volume of 38414993 shares. The stock had previously closed at $4.45. Get **Relmada Therapeutics** alerts: ## Wall Street Analyst Weigh In A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Relmada Therapeutics in a research note on Wednesday, January 28th. Jefferies Financial Group started coverage on shares of Relmada Therapeutics in a report on Monday, December 22nd. They issued a "buy" rating and a $9.00 price target on the stock. Lucid Cap Mkts upgraded shares of Relmada Therapeutics to a "strong-buy" rating in a research note on Monday, March 2nd. Mizuho upgraded Relmada Therapeutics from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $1.00 to $10.00 in a report on Wednesday, November 19th. Finally, Leerink Partners upgraded Relmada Therapeutics from a "market perform" rating to an "outperform" rating and set a $8.00 target price on the stock in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $9.00. **View Our Latest Report on RLMD** ## Relmada Therapeutics Price Performance The stock has a fifty day moving average of $4.13 and a 200 day moving average of $3.21. The stock has a market cap of $534.38 million, a price-to-earnings ratio of -4.07 and a beta of 0.72. ## Insider Activity at Relmada Therapeutics In related news, CFO Maged Shenouda bought 11,665 shares of the company's stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average price of $4.12 per share, for a total transaction of $48,059.80. Following the acquisition, the chief financial officer owned 800,000 shares of the company's stock, valued at approximately $3,296,000. This trade represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 20.70% of the company's stock. ## Hedge Funds Weigh In On Relmada Therapeutics A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new position in Relmada Therapeutics in the fourth quarter valued at approximately $35,041,000. Squadron Capital Management LLC purchased a new position in shares of Relmada Therapeutics in the 4th quarter valued at $32,361,000. Adage Capital Partners GP L.L.C. acquired a new stake in Relmada Therapeutics during the 4th quarter worth $20,624,000. Spruce Street Capital LP purchased a new stake in Relmada Therapeutics in the fourth quarter valued at $19,736,000. Finally, Marshall Wace LLP boosted its stake in Relmada Therapeutics by 1,072.4% in the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company's stock valued at $15,406,000 after acquiring an additional 2,917,609 shares in the last quarter. 45.24% of the stock is currently owned by hedge funds and other institutional investors. ## About Relmada Therapeutics (Get Free Report) Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada's research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications. Relmada's lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings. ## Read More - Five stocks we like better than Relmada Therapeutics - The gold chart Wall Street is terrified of… - America’s 1776 happening again - What a Former CIA Agent Knows About the Coming Collapse - Elon Musk already made me a “wealthy man” - Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Relmada Therapeutics Right Now? Before you consider Relmada Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list. While Relmada Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform](https://longbridge.com/en/news/282587297.md) - [Gossamer Bio Receives Nasdaq Minimum Bid Price Deficiency Notice](https://longbridge.com/en/news/282247265.md) - [Allogene's blood cancer therapy delays cancer relapse in mid-stage study](https://longbridge.com/en/news/282537381.md) - [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md) - [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)